This multisystem disorder is characterized by the presence of at least one of the following: (1) diffuse thyroid enlargement with hyperthyroidism, (2) infiltrative ophthalmopathy, or (3) infiltrative dermopathy. The latter two components are of importance, but space constraints prevent further descriptions here. An excellent review of endocrine ophthalmopathy has recently appeared.Ŵ ith the discovery of long-acting thyroid stimulator (LATS) in the serum of Graves' disease patients by Adams and Purvis in 1956 , the disease became associated with autoimmune phenomenon.^ Subsequently, LATS, LATS protector, and human thyroid stimulator have been identified as immunoglobulins present in Graves' disease serum which stimulate the thyroid follicular cell.'*"^ These various stimulators, collectively termed thyroid-stimulating immunoglobulins (TSi), are IgG molecules acting as antibodies with thyroid-stimulating activity residing in the Fab fragment." TSI are almost invariably found in patients with active, untreated Graves' disease and appear to bind to the thyrotropin-stimulating hormone (TSH) receptor as their antigen."-'^ Other autoantibodies directed against either thyroglobulin or microsomal antigens can be identified in Graves' disease by sensitive assays.** Such antibodies are not felt to play an important role in pathogenesis and appear to correlate directly with the degree of hyperthyroidism.
Organ-specific, cell-mediated immunity is also present in Graves' disease and Hashimoto's thyroiditis. In the direct leukocyte migration test, lymphocytes not sen-0011 -9059/81 /0400/0207/$00,80 © International Society of Tropical Dermatology, Inc, 207 sitized to L1 particular antigen will migrate when exposed to that antigen. However, when previously sensitized lymphocytes are exposed to that antigen, migration inhil)ition factor (MIF) is produced and leukocyte migration decreases. Lymphocytes from patients with Graves' disease or Hashimoto's thyroiditJs show marked inhibition of migration when exposed to particulate thyroid antigen, while normals do not.'" Similarly, Graves' disease lymphocytes produce TSI when exposed to phytohemagglutinin while normals do not." Thus, Graves' disease lymphocytes manifest both organspecific, cell-mediated and humoral immunity. Graves' disease appears to be a receptor-antibody disease in which autoantibodies stimulate the thyroid gland directly by their specificity for the TSH receptor. Graves' disease appears to be inherited as a polygenic tract, with TSI and Graves' disease present in 50 percent and 5 percent of siblings, respectively. Although increased frequency of HLA-B8 and Dw3 is seen in whites and Bw35 in Japanese with Graves' disease, this probably represents linkage dysequilibrium with a still yet unidentified gene.
Diagnosis
At any given time, a patient with Graves' disease may possess only one of its three major manifestations. In a particular patient, one or two of the manifestations may never appear; moreover, these three manifestations seem to occur and progress independently of each other in most patients. Thus, the patient's presentation varies with the manifestations present, their severity, the age of the patient, and any preexisting organ dysfunction. A diffuse goiter with hyperthyroidism is the most common manifestation of Graves' disease. The goiter typically has a spongy consistency with size varying from 30 to 120 gm estimated by palpation. Other signs of hyperthyroidism are lid lag and/or retraction, proptosis, stare, tremor, tachycardia, thyroid bruit, and velvety moist skin. When the majority of signs are present, an unmistakable picture results, but many patients with hyperthyroidism present with a paucity of signs. The major symptoms of hyperthyroidism are nervousness, heat intolerance, fatigue, weight loss, increased perspiration, palpitations, and hyperdefecation. Nervousness predominates in younger patients, while cardiovascular symptoms are more often reported in the elderly.
Once the diagnosis of hyperthyroidism is considered, confirmation is usually achieved by measurement of serum thyroxine (T4} concentration by radio immunoassay or competitive protein-binding analysis.'^-'^ However, serum T4 elevations are not pathognomonic of hyperthyroidism since alterations in the serum thyroxinebinding globulin (TBG) concentrations directly influence serum T4. To determine if elevated T4 values are due to hyperthyroidism or elevated TBG levels, estimation or direct measurement of the free (unbound) T4 value is necessary. In most situalions, estimation of the free serum T4 concentration (free T4 index) suffices. The free T4 index (FTI or 17) is the product of the total serum T4 value and the Ii resin uptake. The T3 resin uptake is inversely proportional to the number of unoccupied T4 binding sites available on TBG. In hyperthyroidism, the number of unoccupied binding sites is low and the T3 resin uptake high; while with TBG elevation, there is a surplus of unoccupied binding sites and the T3 resin uptake is low. Although free T4 concentration can be measured directly by equilibrium dialysis or radioimmunoassay, these techniques are not widely available and have not been shown to be superior to the FTI in clinical practice.'•*-'^ Elevated FTI values are virtually diagnostic of hyperthyroidism in the appropriate clinical setting.
Most hyperthyroid patients demonstrate elevated serum T4 and T3 (triiodothyronine) concentrations. However, in occasional hyperthyroid patients, FTI values are normal, butT3 values are high.'^ In the euthyroid subject, 80 percent of serum T3 is derived from peripheral deiodination of T4 rather than from thyroidal secretion; and T3 exerts the major effect of thyroid hormones on tissues.'^ In hyperthyroidism, mean serum 14 and T3 concentrations are two to three and three to four times the normal concentrations, respectively.'" Because of this disproportionate increase, some hyperthyroid patients demonstrate elevated T3 but normal FTI values (T3 thyrotoxicosis).
In some clinically hyperthyroid patients, equivocal elevations of FTI and T3 values cast doubt upon the diagnosis. To clarify the situation, tests assessing the integrity of the pituitary-thyroid axis, such as thyrotropinreleasing hormone (TRH) stimulation orT3 suppression, are required. Following TRH infusion, euthyroid subjects demonstrate a prompt rise in TSH, while hyperthyroid patients show no significant response (Fig. 1) . Lack of TSH response to TRH is invariably seen in hyperthyroidism, but also occurs frequently in euthyroid Graves'disease and with autonomous thyroid adenoma.'" Because of simplicity and rapidity, the TRH stimulation test has largely supplanted the T3 suppression test. A useful scheme for investigation of suspected thyrotoxicosis is shown in Fig. 2 .
Treatment
When Graves' disease with hyperthyroidism is confirmed, three therapeutic options are available: (1) antithyroid drugs, (2) surgery, and (3) radioiodine. All of these modalities can produce temporary or permanent cure of the disease. Drugs employed to treat hyperthyroidism either hove a direct effect on the thyroid (thionamides, iodide, or lithium) or block the peripheral effect of thyroid hormone (^-receptor blockers). The thionamides (propylthiouracil and methimazole) block thyroid hormone synthesis by inhibiting multiple steps in the T4, T3 pathway.
Such inhibition normalizes serum T4, TJ concentrations and depletes intrathyroid 14, T3 content. The amount of drug required to inhibit synthesis varies considerably and is determined in an individual patient by increasing the dose gradually until the desired effect is achieved. The thionamides probably do not influence the natural history of the disease, but control it for long intervals (months to years) waiting for a spontaneous remission. Unfortunately, current information demonstrates a progressive, unexplained fall in remission rate to less than 15 percent in unselected series.^" Other investigators have shown that persistence of thyroid-stimulating immunoglobulins or failure of decline in serum thyroglobulin during thionamide therapy are good predictors of relapse.^'••" Perhaps these indicators will prove useful in palient selection for long-term thionamide therapy. Both iodide and lithium impair thyroid hormone synthesis and block release of formed hormone. They have proven useful as supplemental agents to control hyperthyroidism, but are of little value when used alone as primary therapy.
FTI
-receptor blocking agents, such as propranolol, reduce the ;8-adrenergic stimulated manifestations ot hyperthyroidism probably through reduction of the synergistic effect of catecholamines and thyroid hormone upon the /H-receptor.^-'' Propranolol also decreases the peripheral conversion of T4 to Ti. However, recent work revealed no significant difference in symptomatic improvement between j8-blockers that do or do not block T4 to T3 conversion.'•^^ The major role of )S-blockers is to provide symptomatic relief until thyrotoxicosis is relieved by definitive therapy. Bronchospasm and cardiac dysfunction are contraindications to propranolol Lise.
Surgery
Preoperative use of thionamides, iodide, and j8-blockers has significantly reduced surgical morbidity and mortality, and subtotal thyroidectomy is the procedure of choice in selected patients. Unfortunately, as thyroid diagnosis and therapy have improved, the number of thyroid procedures and experienced thyroid surgeons has declined. As thyroidectomy experience declines, complications increase, as noted in a national survey review which revealed an overall mortality of 0.2 percent and the morbidity of 3 percent permanent hypoparathyroidism.^'' The incidence of iatrogenic hypothyroidism is inversely proportional to the hyperthyroidism recurrence rate.
Radioiodine
Despite the recognized high incidence of iatrogenic hypothyroidism, 1-131 is the most commonly used treatment modality because of its ease of administration, low cost, and lack of serious side effects. However, concern over possible long-term untoward effects, such as genetic damage, thyroid cancer, or leukemia, has restricted 1-13Ts use in many centers. Fortunately, longterm follow-up studies have not identified such detrimental effects to date.^®"^^ Recently, the gonadal radiation dose following 1-131 therapy has been shown to be no more than that realized from an IVP or barium enema.^^C
hoice of Therapy
The therapy selected by the patient and the treating physician are dependent upon many factors, such as patient age, concurrent disease, and individual preferences. I prefer radioiodine therapy for most hyperthyroid patients with the following exceptions. Radioiodine therapy is absolutely contraindicated during pregnancy, and such patients are Ijest managed wilh the thionamides alone through pregnancy. After delivery, thionamides are stopped and radioiodine admini^.-tered. Hyperthyroid patients with goiter-induced local compression symptoms should be treated surgically after adequate preoperative preparation.
Treatment of children with Graves' disease is a controversial issue. An initial trial of thionamide therapy of up to one year appears warranted in cooperative children, though remission rates of less than 30 percent are expected.™ If spontaneous remission does not occur, 1-131 therapy should be given, since it is safe and effective."'^'' Some thyroid surgeons advocate total thyroidectomy in children less than lOyearsof age to decrease the recurrence rate.^'"''^ This must add to the morbidity rates in these children.
Hashimoto's Thyroiditis
This chronic destructive thyroiditis is characterized pathologically by diffuse lymphocytic infiltration, varying degrees of fibrosis, and foliicular cell atrophy of the thyroid. Since Roitt first described the presence of circulating autoantibodies in patients with Hashimoto's thyroiditis, this disease has been accepted by many as an autoimmune disease.^^ However, despite intensive investigation, our knowledge of its pathogenesis remains limited. Thyroidal antigens, such as thyroglobulin, are routinely released into the systemic circulation, yet this "exposure" of antigens does not normally induce thyroidal autoantibody synthesis. However, in patients with a defect in suppression T cell function, as postulated by Voipe, these normal antigens sensitize a forbidden clone of T lymphocytes.^' These sensitized lymphocytes differentiate into (1) helper T cells which induce B lymphocyte production of autoantibodies, and (2) killer T cells which attack the thyroid directly. Thyroglobulin-antithyroglobulin complexes appear cytotoxic in vitro, and thyroid autoantibodies can apparently be cytotoxic in cooperation with killer T ceils,•''•Â gain, as in Graves' disease, the immune surveillance defect is a prerequisite for initiation of autoimmune thyroid disease. Such a defect appears inheritable as a polygenic tract with the presence of thyroid antibodies and overt thyroid disease in 50 percent and 25 percent, respectively, of siblings of involved patients.-'**"''** No association with specific histocompatibility antigens has been demonstrated.
Hashimoto's thyroiditis is the most common thyroid disease in the U.S., with an estimated prevalence of one to three percent of the population. The disease is usually detected by the physician's discovery of an asymptomatic small goiter which gradually enlarges if untreated. Hypothyroidism or occasionally, hyperthyroidism develop In the majority of patients with time.
Diagnosis
The presence of a goiter in a child or young adult strongly suggests Hashimoto's thyroiditis, which can be detected in more than 50 percent of such patients. Classically, the goiter is firm, with a bosselated surface, nontender, and less than 50 gm in size. If the patient is clinically euthyroid or hypothyroid, a FTI, serum TSH, and thyroid antibodies are drawn initially. Since the disease presents no singly distinguishing feature, the use of multiple diagnostic criteria improves diagnostic accuracy (Table 1) .'''' If two or three criteria are present, the likelihood of Hashimoto's thyroiditis is greater than 65 percent and 85 percent respectively.
As thyroid destruction proceeds, serum TSH progressively increases to stimulate thyroidal T4, Ti production to maintain euthyroidism until hypothyroidism ensues. Thyroid antibodies in high titer are present in most patients with Hashimoto's thyroiditis. The assay procedure used most commonly is tanned red cell agglutination (TRCA) to detect either antithyroglobulin (ATG) or antimicrosomal antibodies (AM).""* Positive TRCA values In patients in whom careful thyroid examination and in vitro studies have not sufficiently confirmed the diagnosis, a technetium pertechnetate thyroid scan should be obtained. Classically, the scan demonstrates enhanced thyroid uptake early with heterogeneous tracer distribution (Fig. 3) . This pattern is not specific, but it is seen in greater than 50 percent with Hashimoto's thyroiditis. In occasional patients, further clarification is possible through either (1) iodine, a common finding in Hashimoto's thyroiditis, or (2) TRH stimulation test demonstrating a TSH hyperresponse indicative of decreased thyroidal reserve.
Treatment
In a euthyroid patient with elevated thyroidal antibodies, no therapy is instituted unless a goiter greater than 30 gm is present. Levothyroxine (0.15 to 0.2 mg/ day) prevents further conspicuous enlargement and decreases goiter size in most. In patients with elevated serum TSH, but normal FTI, the majority develop clinically detectable hypothyroidism over a three-year bllow-up, and should he treated when the elevated TSH is detected with levothyroxine as above.
•" Likewise, patients with elevated serum TSH and low serum FTI are hypothyroid, and levothyroxine therapy Is required even if patient is asymptomatic.
Conclusions
The autoimmune thyroid diseases develop in a predisposed population with a defect in immune surveillance. This defect allows production of thyroid-directed autoantibodies that are either stimulatory to (TSI) or destructive of (antimicrosomal) the patient's thyroid gland. Proper diagnosis and therapy requires an understanding ofthe specific immunologic mechanisms involved, their sequelae, and corrective measures ofthe induced thyroid dysfunction.
